Abstract
Most of the classical drugs used today to destroy cancer cells lead to the development of acquired resistance in those cells by limiting cellular entry of the drugs or exporting them out by efflux pumps. As a result, higher doses of drugs are usually required to kill the cancer cells affecting normal cells and causing numerous side effects. Accumulation of the therapeutic level of drugs inside the cancer cells is thus required for an adequate period of time to get drugs’ complete therapeutic efficacy minimizing the side effects on normal cells. In order to improve the efficacy of chemotherapeutic drugs, nanoparticles of carbonate apatite and its strontium (Sr2+)-substituted derivative were used in this study to make complexes with three classical anticancer drugs, methotrexate, cyclophosphamide and 5-flurouracil. The binding affinities of these drugs to apatite were evaluated by absorbance and HPLC analysis and the therapeutic efficacy of drug-apatite complexes was determined by cell viability assay. Carbonate apatite demonstrated significant binding affinity towards methotrexate and cyclophosphamide leading to more cellular toxicity than free drugs in MCF-7 and 4T1 breast cancer cells. Moreover, Sr2+ substitution in carbonate apatite with resulting tiny particles less than 100 nm in diameter further promoted binding of methotrexate to the nanocarriers indicating that Sr2+-substituted apatite nanoparticles have the high potential for loading substantial amount of anti-cancer drugs with eventual more therapeutic effectiveness.
Keywords: Anticancer drugs, Carbonate apatite, Cyclophosphamide, 5-flurouracil, Methotrexate, Strontium.
Current Drug Delivery
Title:Methotrexate- and Cyclophosphamide-embedded Pure and Strontiumsubstituted Carbonate Apatite Nanoparticles for Augmentation of Chemotherapeutic Activities in Breast Cancer Cells
Volume: 11 Issue: 2
Author(s): Snigdha Tiash, Iekhsan Othman, Rosita Rosli and Ezharul Hoque Chowdhury
Affiliation:
Keywords: Anticancer drugs, Carbonate apatite, Cyclophosphamide, 5-flurouracil, Methotrexate, Strontium.
Abstract: Most of the classical drugs used today to destroy cancer cells lead to the development of acquired resistance in those cells by limiting cellular entry of the drugs or exporting them out by efflux pumps. As a result, higher doses of drugs are usually required to kill the cancer cells affecting normal cells and causing numerous side effects. Accumulation of the therapeutic level of drugs inside the cancer cells is thus required for an adequate period of time to get drugs’ complete therapeutic efficacy minimizing the side effects on normal cells. In order to improve the efficacy of chemotherapeutic drugs, nanoparticles of carbonate apatite and its strontium (Sr2+)-substituted derivative were used in this study to make complexes with three classical anticancer drugs, methotrexate, cyclophosphamide and 5-flurouracil. The binding affinities of these drugs to apatite were evaluated by absorbance and HPLC analysis and the therapeutic efficacy of drug-apatite complexes was determined by cell viability assay. Carbonate apatite demonstrated significant binding affinity towards methotrexate and cyclophosphamide leading to more cellular toxicity than free drugs in MCF-7 and 4T1 breast cancer cells. Moreover, Sr2+ substitution in carbonate apatite with resulting tiny particles less than 100 nm in diameter further promoted binding of methotrexate to the nanocarriers indicating that Sr2+-substituted apatite nanoparticles have the high potential for loading substantial amount of anti-cancer drugs with eventual more therapeutic effectiveness.
Export Options
About this article
Cite this article as:
Tiash Snigdha, Othman Iekhsan, Rosli Rosita and Chowdhury Hoque Ezharul, Methotrexate- and Cyclophosphamide-embedded Pure and Strontiumsubstituted Carbonate Apatite Nanoparticles for Augmentation of Chemotherapeutic Activities in Breast Cancer Cells, Current Drug Delivery 2014; 11 (2) . https://dx.doi.org/10.2174/1567201810666131211101819
DOI https://dx.doi.org/10.2174/1567201810666131211101819 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytostatic and Cytotoxic Activity of Synthetic Diterpene Derivatives Obtained from (-)-Kaur-9(11), 16-Dien-19-Oic Acid Against Human Cancer Cell Lines
Letters in Drug Design & Discovery Lectins as Ligands for Directing Nanostructured Systems
Current Drug Delivery Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry Data-driven Approach to Detect and Predict Adverse Drug Reactions
Current Pharmaceutical Design Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) – a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
Current Pharmaceutical Design Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment
Current Cancer Therapy Reviews Disorders of Mechanisms of Calcium Metabolism Control as Potential Risk Factors of Prostate Cancer
Current Medicinal Chemistry Synthesis of New and Known Dicoumarols in Aqueous Media: A Green and Convenient Procedure Promoted by Titanium(IV) Oxide Nanoparticles
Letters in Organic Chemistry Novel Molecular Targets in Cancer Chemotherapy Waiting for Discovery
Current Medicinal Chemistry - Anti-Cancer Agents Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer
Current Pharmaceutical Design Therapeutic Potential of Carbon Monoxide (CO) for Intestinal Inflammation
Current Medicinal Chemistry Estimation of specific activity of 177Lu by `saturation assay` principle using DOTA as ligand
Current Radiopharmaceuticals Molecular Docking and In Silico ADMET Study Reveals Flavonoids as a Potential Inhibitor of Aromatase
Letters in Drug Design & Discovery Phytosterols in Cancer: From Molecular Mechanisms to Preventive and Therapeutic Potentials
Current Medicinal Chemistry Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Targeting Platinum Resistant Disease in Ovarian Cancer
Current Medicinal Chemistry